Ezetimibe/simvastatin (INEGY™) in the treatment of hyperlipidaemia

被引：16

作者：

Kastelein, JJP ^{[1
]}

Sankatsing, RR ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2005年 / 59卷 / 12期

关键词：

ezetimibe; simvastatin; INEGY (TM); low-density lipoprotein cholesterol; lipids;

D O I：

10.1111/j.1368-5031.2005.00737.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ezetimibe/simvastatin (INEGY(TM)), a dual inhibitor of both cholesterol production and absorption, is a new approach to the management of hyperlipidaemia. Recent studies have shown that it produces greater reductions in low-density lipoprotein (LDL) cholesterol than the single inhibition of statin therapy, enabling many more patients to achieve their LDL cholesterol treatment goals. With ezetimibe/simvastatin therapy, reductions of up to 61% from baseline have been seen in LDL cholesterol, with clear improvements in other associated lipid fractions. It has been well tolerated across all studies, with a safety profile similar to that of statin therapy. This article will review clinical experience to date with ezetimibe/simvastatin, commenting upon its place and potential value in the prevention of cardiovascular disease.

引用

页码：1464 / 1471

页数：8

共 51 条

[41] Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein [J].

Sager, PT ;

Melani, L ;

Lipka, L ;

Strony, J ;

Yang, B ;

Suresh, R ;

Veltri, E .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (12) :1414-1418

[42] Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - The MIRACL study: A randomized controlled trial [J].

Schwartz, GG ;

Olsson, AG ;

Ezekowitz, MD ;

Ganz, P ;

Oliver, MF ;

Waters, D ;

Zeiher, A ;

Chaitman, BR ;

Leslie, S ;

Stern, T .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (13) :1711-1718

[43] Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial [J].

Smilde, TJ ;

van Wissen, S ;

Wollersheim, H ;

Trip, MD ;

Kastelein, JJP ;

Stalenhoef, AFH .

LANCET, 2001, 357 (9256) :577-581

[44] Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin [J].

Stein, E ;

Stender, S ;

Mata, P ;

Sager, P ;

Ponsonnet, D ;

Melani, L ;

Lipka, L ;

Suresh, R ;

MacCubbin, D ;

Veltri, E .

AMERICAN HEART JOURNAL, 2004, 148 (03) :447-455

[45] The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment [J].

Stein, E .

ATHEROSCLEROSIS SUPPLEMENTS, 2002, 2 (04) :19-25

[46] Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) [J].

Strandberg, TE ;

Pyörälä, K ;

Cook, TJ ;

Wilhelmsen, L ;

Faergeman, O ;

Thorgeirsson, G ;

Pedersen, TR ;

Kjekshus, J .

LANCET, 2004, 364 (9436) :771-777

[47] Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function [J].

van Heek, M ;

Farley, C ;

Compton, DS ;

Hoos, L ;

Davis, HR .

BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (02) :409-417

[48]

VanHeek M, 1997, J PHARMACOL EXP THER, V283, P157

[49] Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe [J].

Wang, J ;

Williams, CM ;

Hegele, RA .

CLINICAL GENETICS, 2005, 67 (02) :175-177

[50] Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias [J].

Wierzbicki, AS ;

Doherty, E ;

Lumb, PJ ;

Chik, G ;

Crook, MA .

CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (03) :333-338

← 1 2 3 4 5 6 →